Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

Exclusion Criteria

• •1. Patients with a history of allergies to rivaroxaban;
• •2. History of recent major or clinically relevant bleeding within the previous 4 weeks.
• •3. Patients with bleeding risks: thrombocytopenia (platelet count \< 50\*109/L), clinically significant active bleeding, active gastric ulcer disease, severe arterial hypertension, history of previous stroke; Inadequate renal function; creatinine clearance \< 30 ml/min；
• •4. Inadequate hepatic function: aminotransferase \> 3 times the upper limit of normal (ULN) (if liver metastasis, alanine aminotransferase \> 5 times the ULN
• •5. Patients requiring strong cytochrome P450 3A4 (CYP3A4) inducers (rifampin, phenobarbital) or strong CYP3A4 inhibitors (HIV protease inhibitor, systemic ketoconazole) treatments.
• •6. Plan of treatment with bevacizumab or other anti-cancer drugs known to increase the bleeding risk.
• •7. Patients who have had anticoagulant drugs for any other reason.
• •8. Women who are pregnant or breastfeeding.